The central ambition of modern diagnostics is the "liquid biopsy"—the ability to understand the state of a specific internal organ by analyzing a simple blood or urine sample. However, a fundamental biological hurdle remains: the body’s circulatory system is a shared reservoir. When a protein, metabolite, or vesicle appears in the blood, it rarely carries a "return address."
Research across oncology, neurology, and immunology has converged on this problem of source attribution. To move from correlation to causation, researchers are developing methods to distinguish whether a systemic signal originates from a localized pathology, a secondary immune response, or unrelated peripheral tissues.
The Reservoir Problem
The difficulty begins with the fact that many biomarkers are produced by multiple tissues. In 1976, G Agrup and H Rorsman identified 3-methoxytyrosine in the urine of melanoma patients (Agrup et al., 1976), but they noted a persistent challenge: determining if such metabolites originate exclusively from the tumor or if other physiological pathways contribute to the total levels.
This ambiguity scales with the complexity of the molecule. For instance, G. Cimasoni found that alkaline phosphatase (ALP) levels in gingival fluid correlate with periodontal disease severity, yet the source remains a "black box"—it could be host bone degradation, migrating immune cells, or even subgingival bacteria (Cimasoni, 1971). Without knowing the primary contributor, clinicians cannot be certain if they are measuring the pathogen's load or the host's defensive response.
The Lineage Challenge in Extracellular Vesicles
Extracellular vesicles (EVs) were once thought to be the solution to this problem. Because these nano-messengers carry protein and RNA cargo from their parent cells, they should theoretically act as "molecular fingerprints."
However, isolating these fingerprints in a living subject is notoriously difficult. Laura Pasetto and Stefano Callegaro have shown that while plasma EVs can accurately diagnose Amyotrophic Lateral Sclerosis (ALS), it remains unclear if these vesicles are shed by dying motor neurons in the central nervous system or by peripheral muscles responding to denervation (Pasetto et al., 2021).
Similarly, in pregnancy, Adrianne L. Stefanski and Nadine Martinez identified specific microRNA surges, but noted that without definitive lineage tracing, it is impossible to confirm if these are direct placental exports or maternal tissues responding to the physiological stress of pregnancy (Stefanski et al., 2019). As Zeyu Huang points out, the inability to distinguish malignant-derived vesicles from those produced by healthy tissue remains a primary barrier to using EVs as precise therapeutic "smart bombs" (Huang et al., 2024).
Distinguishing Local Damage from Systemic Response
In acute injuries like stroke, the timing of a biomarker's appearance often complicates its interpretation. Xinwei He and Yuyan Bao observed that serum periostin levels rise days after an ischemic event (He et al., 2018). But is this periostin leaking from the damaged brain, or is it a systemic production by other organs under stress?
This "spatial resolution" problem is even more acute in critical illness. Junru Wu and Anthony R. Cyr found that trauma and COVID-19 cause massive lipidomic shifts in the blood, but these profiles do not reveal which specific organ systems are failing or recovering (Wu et al., 2022).
Toward Mechanistic Source Mapping
The field is moving toward resolving these ambiguities by mapping the specific enzymatic and cellular pathways that generate biomarkers.
- Enzymatic Foundations: Masaya Matsuzaki and colleagues recently identified ADAMTS4 as the enzyme responsible for a key Alzheimer’s biomarker, providing a mechanistic link that helps researchers determine if the signal in the blood truly reflects brain-specific pathology (Matsuzaki et al., 2023).
- Multi-Omic Integration: By combining plasma proteomics with whole-body imaging, Zirui Fan and Julio A. Chirinos have begun creating "pan-organ" maps that bridge the gap between circulating proteins and clinical anatomy (Fan et al., 2025).
- Cell-Specific Signatures: In transplant medicine, Tej D. Azad and Timothy E. Sweeney developed a 3-gene signature to detect subclinical graft injury. Their work highlights the necessity of distinguishing signals shared by multiple cell types—like macrophages and endothelial cells—to pinpoint the exact site of injury (Azad et al., 2018).
The intuition behind this research direction is that a biomarker's value is not just in its concentration, but in its provenance. Only by resolving the cellular and tissue-specific sources of these signals can we transform the "common sewer" of systemic circulation into a precise map of human health.